Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features.

Haakensen VD, Lingjaerde OC, Lüders T, Riis M, Prat A, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord D, Bukholm IK, Johannesen TB, Perou CM, Ursin G, Kristensen VN, Børresen-Dale AL, Helland A.

BMC Med Genomics. 2011 Nov 1;4:77. doi: 10.1186/1755-8794-4-77.

2.

Artificially induced epithelial-mesenchymal transition in surgical subjects: its implications in clinical and basic cancer research.

Aoyagi K, Minashi K, Igaki H, Tachimori Y, Nishimura T, Hokamura N, Ashida A, Daiko H, Ochiai A, Muto M, Ohtsu A, Yoshida T, Sasaki H.

PLoS One. 2011 Apr 21;6(4):e18196. doi: 10.1371/journal.pone.0018196.

3.

Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression.

Bissell MJ, Hines WC.

Nat Med. 2011 Mar;17(3):320-9. doi: 10.1038/nm.2328. Review.

4.

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.

Fan C, Prat A, Parker JS, Liu Y, Carey LA, Troester MA, Perou CM.

BMC Med Genomics. 2011 Jan 9;4:3. doi: 10.1186/1755-8794-4-3.

5.

Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer.

Cichon MA, Degnim AC, Visscher DW, Radisky DC.

J Mammary Gland Biol Neoplasia. 2010 Dec;15(4):389-97. doi: 10.1007/s10911-010-9195-8. Epub 2010 Dec 16. Review.

6.

Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers.

Camp JT, Elloumi F, Roman-Perez E, Rein J, Stewart DA, Harrell JC, Perou CM, Troester MA.

Mol Cancer Res. 2011 Jan;9(1):3-13. doi: 10.1158/1541-7786.MCR-10-0372. Epub 2010 Dec 3.

7.

Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors.

Trujillo KA, Heaphy CM, Mai M, Vargas KM, Jones AC, Vo P, Butler KS, Joste NE, Bisoffi M, Griffith JK.

Int J Cancer. 2011 Sep 15;129(6):1310-21. doi: 10.1002/ijc.25788. Epub 2011 Feb 11.

8.

Endogenous versus tumor-specific host response to breast carcinoma: a study of stromal response in synchronous breast primaries and biopsy site changes.

Wu JM, Beck AH, Pate LL, Witten D, Zhu SX, Montgomery KD, Allison KH, van de Rijn M, West RB.

Clin Cancer Res. 2011 Feb 1;17(3):437-46. doi: 10.1158/1078-0432.CCR-10-1709. Epub 2010 Nov 22.

9.

Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium.

Graham K, Ge X, de Las Morenas A, Tripathi A, Rosenberg CL.

Clin Cancer Res. 2011 Jan 15;17(2):236-46. doi: 10.1158/1078-0432.CCR-10-1369. Epub 2010 Nov 8.

10.

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.

Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM.

Breast Cancer Res. 2010;12(5):R68. doi: 10.1186/bcr2635. Epub 2010 Sep 2.

11.

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes.

Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15449-54. doi: 10.1073/pnas.1004900107. Epub 2010 Aug 16. Erratum in: Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19132.

12.

Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression.

Foubert E, De Craene B, Berx G.

Breast Cancer Res. 2010;12(3):206. doi: 10.1186/bcr2585. Epub 2010 Jun 25. Review.

13.

Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients.

de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, Kuppen PJ, Tollenaar RA, Mesker WE.

Breast Cancer Res Treat. 2011 Feb;125(3):687-96. doi: 10.1007/s10549-010-0855-6. Epub 2010 Apr 2.

PMID:
20361254
14.

Interleukin-6 induces increased motility, cell-cell and cell-substrate dyshesion and epithelial-to-mesenchymal transformation in breast cancer cells.

Sehgal PB.

Oncogene. 2010 Apr 29;29(17):2599-600; author reply 2601-3. doi: 10.1038/onc.2010.4. Epub 2010 Feb 8. No abstract available.

15.

Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.

Sharma M, Beck AH, Webster JA, Espinosa I, Montgomery K, Varma S, van de Rijn M, Jensen KC, West RB.

Breast Cancer Res Treat. 2010 Sep;123(2):397-404. doi: 10.1007/s10549-009-0654-0. Epub 2009 Dec 1.

16.

Activation of host wound responses in breast cancer microenvironment.

Troester MA, Lee MH, Carter M, Fan C, Cowan DW, Perez ER, Pirone JR, Perou CM, Jerry DJ, Schneider SS.

Clin Cancer Res. 2009 Nov 15;15(22):7020-8. doi: 10.1158/1078-0432.CCR-09-1126. Epub 2009 Nov 3.

17.

Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression.

Tuhkanen H, Soini Y, Kosma VM, Anttila M, Sironen R, Hämäläinen K, Kukkonen L, Virtanen I, Mannermaa A.

BMC Cancer. 2009 Aug 20;9:289. doi: 10.1186/1471-2407-9-289.

18.

Mammary field cancerization: molecular evidence and clinical importance.

Heaphy CM, Griffith JK, Bisoffi M.

Breast Cancer Res Treat. 2009 Nov;118(2):229-39. doi: 10.1007/s10549-009-0504-0. Epub 2009 Aug 15. Review.

PMID:
19685287
19.

Mutations in p53, p53 protein overexpression and breast cancer survival.

Rossner P Jr, Gammon MD, Zhang YJ, Terry MB, Hibshoosh H, Memeo L, Mansukhani M, Long CM, Garbowski G, Agrawal M, Kalra TS, Gaudet MM, Teitelbaum SL, Neugut AI, Santella RM.

J Cell Mol Med. 2009 Sep;13(9B):3847-57. doi: 10.1111/j.1582-4934.2008.00553.x. Epub 2008 Oct 16.

20.

The basics of epithelial-mesenchymal transition.

Kalluri R, Weinberg RA.

J Clin Invest. 2009 Jun;119(6):1420-8. doi: 10.1172/JCI39104. Review. Erratum in: J Clin Invest. 2010 May 3;120(5):1786.

Supplemental Content

Support Center